What is new in the treatment of steroid-induced osteoporosis?

被引:6
|
作者
Liu, Rosemarie H. [1 ]
Werth, Victoria P. [2 ,3 ]
机构
[1] Yale New Haven Med Ctr, Dept Internal Med, New Haven, CT 06504 USA
[2] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA
[3] VA Hosp, Philadelphia, PA USA
关键词
osteoporosis; glucocorticoids; treatment; calcium; vitamin D; calcitonin; bisphosphonates; parathyroid hormone;
D O I
10.1016/j.sder.2008.03.004
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Glucocorticoid-induced osteoporosis (GIOP) is a serious complication resulting from long-term steroid treatment. In addition to several nonpharmacologic therapies recommended by the American College of Rheumatology, various pharmacologic therapies, such as calcium, vitamin D, hormone-replacement therapy, calcitonin, and bisphosphonates, can be used to prevent and/or treat GIOP. Bisphosphonates, which are potent inhibitors of bone resorption, are considered the most effective and first-line agents for increasing bone mineral density and decreasing the risk of fracture. Human parathyroid hormone has emerged as a promising agent for the treatment of severe GIOP when used alone or in combination with a bisphosphonate.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条